UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR- mutated non-small-cell lung cancer

Current oncology (Toronto), 2020-12, Vol.27 (6), p.321-329

2020

Volltextzugriff (PDF)

926P Utility of point-of-care genomic profiling in the diagnosis and treatment of cancer of unknown primary

Annals of oncology, 2022-09, Vol.33, p.S969-S970

2022

Volltextzugriff (PDF)

Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer

Current oncology (Toronto), 2019-02, Vol.26 (1), p.37-42

2019

Volltextzugriff (PDF)

KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC

International journal of radiation oncology, biology, physics, 2024-01, Vol.118 (1), p.e14

2024

Volltextzugriff (PDF)

1327P First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)

Annals of oncology, 2023-10, Vol.34, p.S766-S766

2023

Volltextzugriff (PDF)

P2.04B.02 Eight Year Outcomes of a Multidisciplinary Lung Cancer Screening Program at a Large Community Centre in Canada

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S218-S218

2024

Volltextzugriff (PDF)

P2.10B.03 Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S248-S248

2024

Volltextzugriff (PDF)

1189TiP Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)

Annals of oncology, 2022-09, Vol.33, p.S1092

2022

Volltextzugriff (PDF)

585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib

Annals of oncology, 2023-11, Vol.34, p.S1698-S1699

2023

Volltextzugriff (PDF)

Fulfilling the potential of real-world evidence for lung cancer in Canada

Current oncology (Toronto), 2019-06, Vol.26 (3), p.157-159

2019

Volltextzugriff (PDF)

P4.17D.06 Pan-Canadian Lung Cancer Observational Study (PALEOS): A Multicentre Ambispective Real-World Database Study in a Publicly Funded Health System

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S422-S422

2024

Volltextzugriff (PDF)

1165P Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial

Annals of oncology, 2021-09, Vol.32, p.S936-S937

2021

Volltextzugriff (PDF)

EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S346-S347

2022

Volltextzugriff (PDF)

940P Programmed death-ligand 1 (PDL1) expression and real-world outcomes in resected, early-stage non-small cell lung cancer (NSCLC)

Annals of oncology, 2022-09, Vol.33, p.S977

2022

Volltextzugriff (PDF)

1582P - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

Annals of oncology, 2019-10, Vol.30, p.v651-v652

2019

Volltextzugriff (PDF)

Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

Annals of oncology, 2019-10, Vol.30, p.v651-v652

2019

Volltextzugriff (PDF)

Pharmacist led proactive follow-up algorithm for advanced EGFR positive NSCLC patients on afatinib

Annals of oncology, 2017-04, Vol.28, p.ii40

2017

Volltextzugriff (PDF)

Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer

Current oncology (Toronto), 2013-04, Vol.20 (2), p.e150-160

2013

Volltextzugriff (PDF)

International variability in the reimbursement of cancer drugs by publically funded drug programs

Current oncology (Toronto), 2012-06, Vol.19 (3), p.e165-176

2012

Volltextzugriff (PDF)

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer

Current oncology (Toronto), 2019-02, Vol.26 (1), p.e81-93

2019

Volltextzugriff (PDF)

OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S33-S34

2022

Volltextzugriff (PDF)

NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib

Annals of oncology, 2019-11, Vol.30, p.ix23-ix24

2019

Volltextzugriff (PDF)

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada

Current oncology (Toronto), 2018-04, Vol.25 (2), p.163-169

2018

Volltextzugriff (PDF)

1969P - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option

Annals of oncology, 2019-10, Vol.30, p.v791-v792

2019

Volltextzugriff (PDF)

Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option

Annals of oncology, 2019-10, Vol.30, p.v791-v792

2019

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(37)
Tagungsberichte
(3)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Life Sciences & Biomedicine
(10)
Oncology
(9)
Humans
(5)
Non-Small-Cell Lung Cancer
(5)
Canada
(4)
Circuit Faults
(4)
Cmos Logic Circuits
(4)
Practice Guideline
(4)
Automatic Testing
(3)
Circuit Synthesis
(3)
Circuit Testing
(3)
Nsclc
(3)
Semiconductor Device Modeling
(3)
Antineoplastic Agents, Immunological - Therapeutic Use
(2)
Clocks
(2)
Cmos Technology
(2)
Digital Systems
(2)
Egfr
(2)
Egfr T790m
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR- mutated non-small-cell lung cancer

926P Utility of point-of-care genomic profiling in the diagnosis and treatment of cancer of unknown primary

Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer

KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC

1327P First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)

P2.04B.02 Eight Year Outcomes of a Multidisciplinary Lung Cancer Screening Program at a Large Community Centre in Canada

P2.10B.03 Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study

1189TiP Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)

585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib

Fulfilling the potential of real-world evidence for lung cancer in Canada

P4.17D.06 Pan-Canadian Lung Cancer Observational Study (PALEOS): A Multicentre Ambispective Real-World Database Study in a Publicly Funded Health System

1165P Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial

EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy

940P Programmed death-ligand 1 (PDL1) expression and real-world outcomes in resected, early-stage non-small cell lung cancer (NSCLC)

1582P - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

Pharmacist led proactive follow-up algorithm for advanced EGFR positive NSCLC patients on afatinib

Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer

International variability in the reimbursement of cancer drugs by publically funded drug programs

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer

OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results

NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada

1969P - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option

Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option

Suchergebnisse filtern